Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pavlos Msaouel

Showing results (161-170 of 246) with videos related to

Pageof 25
Sort By:
The Oncologist|April 11, 2025
A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCCAndrew W Hahn, Nabil Adra, Ulka Vaishampayan, et al.
European Urology Focus|September 22, 2024
Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell CarcinomaEmily Wang, Eric S Rupe, Sagar S Mukhida, et al.
JCO Oncology Practice|September 21, 2020
Fear of Cancer Recurrence in Patients With Localized Renal Cell CarcinomaCristiane Decat Bergerot, Dena Battle, Errol J Philip, et al.
ESMO Open|November 24, 2020
Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trialsAndrew W Hahn, Omar Alhalabi, Pavlos Msaouel, et al.
European Urology Oncology|July 16, 2024
Clinical Characteristics, Management, and Outcomes of Patients with Renal Medullary Carcinoma: A Single-center Retrospective Analysis of 135 PatientsJustin M Lebenthal, Panayiotis D Kontoyiannis, Andrew W Hahn, et al.
Cancers|May 5, 2021
Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary CarcinomaAndrew J Wiele, Devaki Shilpa Surasi, Priya Rao, et al.
Urologic Oncology|July 5, 2025
Vigorous physical activity as a potential environmental risk factor in renal medullary carcinomaDaniel D Shapiro, Sagar S Mukhida, Andrew W Hahn, et al.
British Journal of Cancer|August 11, 2025
Bayesian interim analysis and efficiency of phase III randomized trialsAlexander D Sherry, Pavlos Msaouel, Avital M Miller, et al.
Journal of the National Cancer Institute|December 10, 2024
Justification, margin values, and analysis populations for oncologic noninferiority and equivalence trials: a meta-epidemiological studyTroy J Kleber, Alexander D Sherry, Andrew J Arifin, et al.
Medrxiv : the Preprint Server for Health Sciences|July 9, 2024
Bayesian Interim Analysis and Efficiency of Phase III Randomized TrialsAlexander D Sherry, Pavlos Msaouel, Avital M Miller, et al.
Pageof 25

Showing results (161-170 of 246) with videos related to

Sort By:
Pageof 25
The Oncologist|April 11, 2025
A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCCAndrew W Hahn, Nabil Adra, Ulka Vaishampayan, et al.
European Urology Focus|September 22, 2024
Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell CarcinomaEmily Wang, Eric S Rupe, Sagar S Mukhida, et al.
JCO Oncology Practice|September 21, 2020
Fear of Cancer Recurrence in Patients With Localized Renal Cell CarcinomaCristiane Decat Bergerot, Dena Battle, Errol J Philip, et al.
ESMO Open|November 24, 2020
Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trialsAndrew W Hahn, Omar Alhalabi, Pavlos Msaouel, et al.
European Urology Oncology|July 16, 2024
Clinical Characteristics, Management, and Outcomes of Patients with Renal Medullary Carcinoma: A Single-center Retrospective Analysis of 135 PatientsJustin M Lebenthal, Panayiotis D Kontoyiannis, Andrew W Hahn, et al.
Cancers|May 5, 2021
Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary CarcinomaAndrew J Wiele, Devaki Shilpa Surasi, Priya Rao, et al.
Urologic Oncology|July 5, 2025
Vigorous physical activity as a potential environmental risk factor in renal medullary carcinomaDaniel D Shapiro, Sagar S Mukhida, Andrew W Hahn, et al.
British Journal of Cancer|August 11, 2025
Bayesian interim analysis and efficiency of phase III randomized trialsAlexander D Sherry, Pavlos Msaouel, Avital M Miller, et al.
Journal of the National Cancer Institute|December 10, 2024
Justification, margin values, and analysis populations for oncologic noninferiority and equivalence trials: a meta-epidemiological studyTroy J Kleber, Alexander D Sherry, Andrew J Arifin, et al.
Medrxiv : the Preprint Server for Health Sciences|July 9, 2024
Bayesian Interim Analysis and Efficiency of Phase III Randomized TrialsAlexander D Sherry, Pavlos Msaouel, Avital M Miller, et al.
Pageof 25